1. India Stocks

  2. •

    Process industries

  3. •

    Chemicals: specialty
Vineet Laboratories Ltd.

Vineet Laboratories Ltd.

37.53
INR
-1.37
(-3.52%)
0.92EPS
31.42P/E
556.60MMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
- -
- -
221.92
174.25
193.5
137.26
77.59
30.93
49.32
Basic EPS, GAAP
- -
- -
- -
-0.01
1.62
6.05
1.14
0.94
-20.89
0.58
0.92
Free Cash Flow per Basic Share
- -
- -
- -
- -
-7.94
6.96
-15.72
-8.57
10.81
-6.88
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
0.84
- -
- -
- -
- -
Book Value per Share
0.01
0.01
0.37
0.36
24.26
30.28
30.7
31.65
13.35
23.74
23.74
Tangible Book Value per Share
0.01
0.01
0.37
0.36
24.26
30.28
30.7
31.65
13.35
23.74
23.74
Basic Weighted Avg Shares
11
11
11
11
11
11
11
11
10
19
12
Sales/Revenue/Turnover
- -
- -
- -
- -
2,435
1,912
2,123
1,506
750
594
594
Operating Margin (%)
- -
- -
- -
- -
2.6
5.83
2.65
3.11
-25.05
10.21
10.21
Depreciation Expense
- -
- -
- -
- -
18
20
24
25
25
24
24
Net Income, GAAP
- -
- -
- -
- -
18
66
13
10
-202
11
11
Effective Tax Rate (%)
- -
- -
- -
- -
56.13
28.97
38.3
- -
- -
13.39
13.39
Profit Margin (%)
- -
- -
- -
- -
0.73
3.47
0.59
0.68
-26.92
1.87
1.87
Working Capital
- -
- -
4
4
117
79
130
122
-70
315
315
LT Debt
- -
- -
- -
- -
35
17
48
39
38
102
102
Total Equity
- -
- -
4
4
266
332
337
347
146
456
456
Return on Invested Capital (%)
- -
- -
- -
- -
11.92
13.75
5.12
- -
- -
7.15
7.15
Return on Capital (%)
- -
- -
- -
- -
11.81
14.13
4.5
- -
- -
7.34
7.34
Return on Common Equity (%)
- -
- -
- -
-2.74
13.18
22.19
3.74
3
-81.79
3.69
3.69

Capital Structure

INR

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
363
- -
351
LT Borrowings
65
- -
102
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
9
19
Market Capitalization
368
339
557

Working Capital

INR

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
647
- -
988
Cash, Cash Equivalents & STI
7
- -
171
Accounts Receivable, Net
43
- -
114
Inventories
567
- -
641
Total Current Liabilities
679
- -
673
Payables & Accruals
- -
- -
- -
ST Debt
363
- -
351
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
36.56%
211.33%
Free Cash Flow
- -
-199.36%
-226.54%
Net Income, GAAP
- -
-399.51%
-105.5%
Sales/Revenue/Turnover
- -
-22.1%
-20.79%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
375
434
326
370
1,506
2025
239
190
181
141
750
2026
74
174
156
189
594

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.14
2.2
-1.88
1.75
0.94
2025
-1.94
-1.66
-6.19
-10.41
-20.89
2026
-0.79
0.36
0.92
0.43
0.58

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Venkata Ramana Gaddam
Full Time Employees
57
Sector
Process industries
Industry
Chemicals: specialty
Address
5-5-160, Malleswari Nilayam Hyderabad TS India 500074
IPO Date
Jun 15, 2021
Website
vineetlabs.co.in
Similar Companies
Petkim Petrokimya Holding Anonim Sirketi (BIST:PETKM)
Albemarle Corporation (NYSE:ALB)
Linde plc (NASDAQ:LIN)
Gubre Fabrikalari T.A.S. (BIST:GUBRF)
IOL Chemicals & Pharmaceuticals Ltd. (NSE:IOLCP)
Dow Inc. (NYSE:DOW)
Business
Vineet Laboratories Limited (VINEETLAB.NS) is an India-based pharmaceutical company that designs, develops, manufactures, and sells active pharmaceutical ingredient (API) intermediates, bulk drugs, and fine chemicals. The company produces API intermediates including Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, and Piroctone Olanine; fine chemicals and reagents such as IPTG, PNPP, X-Gal, ATCA, Butyl Lithium, Furaldehyde, Butylnitrite, and Aminouracil; and custom synthesis molecules for multinational clients. Incorporated in 2016 and headquartered in Hyderabad, Telangana, with manufacturing facilities in Malkapur Village, Yadadri Bhuvanagiri District, the ISO 9001:2015-certified firm operates a multipurpose plant equipped for complex reactions, including low-temperature processes down to -100°C and handling pyrophoric chemicals. It serves domestic and international customers in the healthcare and pharmaceuticals sectors, exporting products to markets including the United States and exporting to clients such as Gilead Sciences and Teva. In recent developments, Vineet Laboratories approved a rights issue in November 2025 to raise Rs. 3,000 lakhs, forming a Rights Issue Committee to oversee the process. The company held its 9th Annual General Meeting on September 25, 2025, following dispatch of the 2024-25 annual report, and in August 2025, its board approved a postal ballot for increasing authorized share capital, raising loan/guarantee/investment thresholds, and appointing Mr. Premananda Reddy Vennapusa as a non-executive director. Promoter holdings decreased in recent quarters, with disclosures of share sales by promoters including Mr. Gaddam Venkata Rama and Mr. Satyanarayana Raju Bhupathiraju in August 2025. These moves follow the company's demerger from Ortin Laboratories Limited's API Intermediates Division in December 2020, enhancing its focus on pharmaceutical intermediates and process technology outsourcing.